The study’s starting point is the World Health Organization and UNAIDS recommendation that treatment should begin as quickly as possible after diagnosis. Rapid initiation suppresses viral replication earlier, preserves immune function, and reduces onward transmission. Yet translating that policy into practice depends on a web of patient-level and structural factors, and evidence from Chinese clinical settings has been sparse. The Beijing team set out to close that gap by analyzing who started therapy rapidly, and whether the timing of initiation — or the choice of drug regimen — shaped long-term outcomes.

Using multivariate logistic regression, the researchers identified two independent predictors of rapid initiation. Patients with higher education levels were more than twice as likely to start therapy rapidly, with an adjusted odds ratio of 2.35 (95% confidence interval 1.12–4.92, P = 0.024). Transmission route also mattered: people who acquired HIV through heterosexual contact were more likely to begin treatment quickly than men who have sex with men, with an adjusted odds ratio of 2.24 (95% CI 1.02–4.91, P = 0.044). These associations suggest that health literacy and patient population characteristics continue to shape access to the fastest standard of care even within a single treatment center.

To track what happened after treatment began, the team employed generalized estimating equations, a statistical framework well suited to repeated measurements collected over time from the same patients. They modeled longitudinal changes in CD4 cell counts, the CD4/CD8 ratio, viral load, body mass index, and a panel of biochemical markers. Within each initiation stratum — rapid versus standard ART — they compared integrase strand transfer inhibitor (INSTI)-based regimens against the conventional efavirenz, lamivudine, and tenofovir disoproxil fumarate combination (EFV/3TC/TDF), estimating effects at baseline, as a mean across follow-up, and as a time interaction.

The virological story that emerged is one of early advantage without long-term divergence. Patients who started therapy rapidly experienced a faster initial decline in viral load, consistent with the theoretical benefit of suppressing replication before the immune system sustains further damage. However, when the researchers tested whether the medication regimen interacted with time to shape viral load and CD4 trajectories, the interaction terms were not statistically significant after false discovery rate correction using the Benjamini–Hochberg procedure. In practical terms, the long-term immunological and virological trajectories of rapid and standard initiation proved comparable over the 36-month median follow-up.

The application of false discovery rate correction across twelve biochemical indices reflects a methodologically careful approach. Longitudinal studies that track many laboratory markers simultaneously face an elevated risk of spurious findings, and the Benjamini–Hochberg correction controls the expected proportion of false positives among declared discoveries. By requiring effects to survive this correction, the team guarded against overinterpreting transient laboratory fluctuations as genuine clinical differences. A propensity-score weighted sensitivity analysis further reinforced the robustness of the comparisons between initiation strategies.

The drug-class comparison produced the study’s most actionable findings. INSTI-based regimens demonstrated superior hepatic safety, with better alanine aminotransferase and aspartate aminotransferase profiles than the EFV/3TC/TDF backbone. Efavirenz-based combinations have long been associated with hepatic and neuropsychiatric toxicity, so the hepatological advantage of integrase inhibitors aligns with expectations. But the INSTI regimens were not without trade-offs: they produced mild elevations in creatinine, a marker of kidney function, and in bilirubin, along with modestly higher total cholesterol and triglyceride levels.

Notably, these safety patterns held consistently across both rapid and standard initiation strata, with no significant medication regimen by time interaction. In other words, the metabolic and renal signals associated with INSTIs appear to be properties of the drug class itself rather than consequences of when therapy is started. This distinction matters for clinicians: the choice between an INSTI backbone and an efavirenz-based regimen carries predictable laboratory consequences regardless of initiation timing, and those consequences warrant proactive monitoring.

The authors conclude that rapid ART was associated with more rapid early viral suppression but no statistically significant divergence in long-term clinical trajectories, and that INSTI-based regimens offered hepatic advantages with modest renal and metabolic trade-offs regardless of initiation timing. Their recommendation is twofold: support the use of rapid initiation with INSTI-based backbones in Chinese HIV care, while instituting proactive surveillance of renal function and lipid metabolism in patients on integrase inhibitors. The findings arrive at a moment when China’s HIV response is scaling up same-day treatment offers, and they suggest that the population-level benefits of rapid start will accrue primarily through earlier suppression and transmission reduction rather than through measurable differences in three-year immune recovery.

Several caveats frame the interpretation. The study is a single-center retrospective cohort, so its findings describe one Beijing treatment population and may not generalize to regions with different patient demographics or care pathways. The identification of education level and transmission route as determinants of rapid initiation also highlights an equity dimension: patients with less formal education and men who have sex with men were less likely to receive the fastest standard of care, a pattern that deserves targeted intervention. The research was funded by the National Key Research and Development Program of China (2022YFC2305004), and the team — led by Yongbing Sun, Bing Song, and Juan Cheng as co-first authors, with Tianjun Jiang as corresponding author — notes that all participants met conditions for exemption from informed consent under the Helsinki Declaration, with ethics approval from the Fifth Medical Center’s Research Ethics Committee. As rapid initiation policies mature worldwide, longitudinal real-world data of this kind will be essential for calibrating both treatment guidelines and the monitoring protocols that accompany newer drug classes.

Subject of Research: Determinants and longitudinal clinical outcomes of rapid antiretroviral therapy initiation in people living with HIV in China

Article Title: Determinants of rapid antiretroviral therapy initiation and its longitudinal clinical outcomes among people living with HIV in China: a single-center retrospective cohort study

Article References: Sun, Y., Song, B., Cheng, J., Zhang, C., Zhen, C., Liang, R., Yang, X., Zhao, Z., & Jiang, T. (2026). Determinants of rapid antiretroviral therapy initiation and its longitudinal clinical outcomes among people living with HIV in China: a single-center retrospective cohort study. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14429-6

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14429-6

Keywords: HIV, rapid ART, antiretroviral therapy, INSTI, CD4 count, viral load, China, cohort study, drug safety, renal function, metabolic markers, WHO guidelines